Table 2.
Treatment and clinical course of patients with systemic autoimmune rheumatic diseases according to the 3-year survival.
| Characteristics | Total (n = 142) | Non-survivor (n = 28) | Survivor (n = 114) | p-value |
|---|---|---|---|---|
| Treatment | ||||
| Steroid | 117 (82.4%) | 26 (92.9%) | 91 (79.8%) | 0.178 |
| Maximal dose (PD, mg) | 30.0 (7.5–50.0) | 30.0 (15.0–40.0) | 30.0 (7.5–50.0) | 0.525 |
| Duration (months) | 12.0 (6.0–30.0) | 10.5 (4.0–16.0) | 16.0 (8.0–36.5) | 0.021 |
| Immunosuppressant | 88 (62.0%) | 19 (67.9%) | 69 (60.5%) | 0.618 |
| Mycophenolate mofetil | 36 (25.4%) | 10 (35.7%) | 26 (22.8%) | 0.244 |
| Azathioprine | 34 (23.9%) | 6 (21.4%) | 28 (24.6%) | 0.920 |
| Cyclosporine | 6 (4.2%) | 2 (7.1%) | 4 (3.5%) | 0.740 |
| Tacrolimus | 14 (9.9%) | 3 (10.7%) | 11 (9.6%) | > 0.999 |
| Antifibrotics* | 8 (5.6%) | 3 (10.7%) | 5 (4.4%) | 0.399 |
| Pirfenidone | 5 (3.5%) | 1 (3.6%) | 4 (3.5%) | 1.000 |
| Nintedanib | 4 (2.8%) | 2 (7.1%) | 2 (1.8%) | 0.365 |
| Clinical outcomes | ||||
| PPF | 21 (14.8%) | 11 (39.3%) | 10 (8.8%) | < .001 |
Significant values are in italics.
PD, prednisolone; PPF, progressive pulmonary fibrosis.
*One patient received pirfenidone followed by nintedanib.